ARCHIVES

NCAB Committee Ok’s Recompetition of OD Support Contract

This article is from The Cancer Letter archive.

Vol. 18 No. 21 | May 22, 1992

Download PDF Visit The Full Archive

Related Articles

Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.

March 2, 2001

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

November 26, 2010

Conversation with The Cancer Letter: Is Republican Control Better Than Two-Party Stalemate?

December 19, 2014

Funding Opportunity: NYC-based Research Alliance Offering $200,000 Per Year for Young Investigators

October 3, 2014

House Committee Urges “Heat Shock” Cancer Center, But Can It Be Done?

July 24, 1998

In Brief: NIH Study Finds Intramural Program Tenures Few Minorities, Calls For Improvements

March 11, 1994